Changes in pulmonary hyperinflation and bronchial hyperresponsiveness following treatment with lansoprazole in children with cystic fibrosis

Pediatric Pulmonology

Volumn 31, Issue 1, 2001, Pages 59-66

  Hendriks, J J E ^a   Kester, A D M ^a   Donckerwolcke, R ^a   Forget, P P ^a   Wouters, E F M ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Body composition; Bronchial hyperresponsiveness; Children; Cystic fibrosis; Fat malabsorption; Lansoprazole; Lung hyperinflation; Proton pump inhibitor; Respiratory muscles force

Indexed keywords

LANSOPRAZOLE;

ARTICLE; BODY COMPOSITION; BODY MASS; BRONCHUS HYPERREACTIVITY; CHILD; CLINICAL ARTICLE; CYSTIC FIBROSIS; FEMALE; HUMAN; LIPID ABSORPTION; LUNG FUNCTION; LUNG INFLATION; MALE; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RESIDUAL VOLUME; TOTAL LUNG CAPACITY; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADIPOSE TISSUE; ADOLESCENT; BODY COMPOSITION; BODY HEIGHT; BODY MASS INDEX; BODY WEIGHT; BRONCHIAL HYPERREACTIVITY; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; ENZYME INHIBITORS; EXOCRINE PANCREATIC INSUFFICIENCY; FECES; FEMALE; FORCED EXPIRATORY VOLUME; H(+)-K(+)-EXCHANGING ATPASE; HUMANS; INSPIRATORY CAPACITY; LIPID METABOLISM; LUNG; MALE; OMEPRAZOLE; PEAK EXPIRATORY FLOW RATE; PROSPECTIVE STUDIES; PROTON PUMPS; RESIDUAL VOLUME; STATISTICS, NONPARAMETRIC; TOTAL LUNG CAPACITY;

EID: 0035129119     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/1099-0496(200101)31:1<59::AID-PPUL1008>3.0.CO;2-H     Document Type: Article

References (40)

1. Duodenal fluid pH in CF
2. Pancrease gastroresistance: In vitro evaluation of pH-determined dissolution
3. Omeprazole enhances the efficacy of pancreatin (pancrease) in CF
4. Effects of a proton-pump inhibitor in CF
5. Improvement of nutritional status and lung function after long-term noctrnal gastrostomy feedings in CF
6. Inspiratory muscle function and body composition in CF
7. Nutritional growth retardation is associated with defective lung growth in CF: A preventable determinant of progressive pulmonary dysfuntion
8. Body composition in children based on anthropometric data. A presentation of normal values
9. The acid steatocrit: A much improved method
10. Acid steatocrit during infancy
11. Clinical use of acid steatocrit
12. Improvement in the accuracy of DEXA for whole body and regional analysis of body composition: Validation using piglets and methodologic considerations in infants
13. Determinants of body composition by DEXA in Dutch children and adolescents
14. Lung function in children and adolescents. Methods, reference values
15. Maximal respiratory pressures: Normal values and relationship to age and sex
16. Which index of PEF is most useful in the management of stable asthma?
17. Resting energy expenditure in clinical pediatrics: Measured versus prediction equations
18. Predicting basal metabolic rate, new standards and review of previous work
19. Height and weight in CF: A cross sectional study
20. Peripheral muscle weakness and exercise capacity in children with CF
21. Respiratory muscle function in CF
22. Respiratory muscle performance in infants and children
23. The effects of nutritional status and hyperinflation on respiratory muscle strength in children and young adults
24. Diaphragmatic function in severely malnourished patients with anorexia nervosa. Effects of renutrition
25. Genotype-phenotype association in infants with CF at the time of diagnosis
26. Surfactant composition in infants and young children with CF
27. Pulmonary surfactant in CF
28. Nebulization of a bovine surfactant in CF: A pilot study
29. Physical and functional properties of airway secretions in CF therapeutic approaches
30. Early pulmonary inflammation in infants with CF
31. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression
32. Wheezing and airflow obstruction during metacholine challenge in children with CF and in normal children
33. New insights on gastro-oesophageal reflux in CF by longitudinal follow up
34. Frequency of gastroesophageal reflux in infants and in young children with CF
35. Gastroesophageal reflux in infants under 6 months with CF
36. Increased peak flow variability in children with asymptomatic hyperresponsiveness
37. Variability of PEF-rate in children: Short and long term reproducibility
38. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with CF